Rajan Radha Rasmi

Rajan Radha Rasmi

Auto-generated profile, based on publicly available information

Rajan Radha Rasmi

Department of Biotechnology, PSG College of Arts and Science, Civil Aerodrome Post, Coimbatore, 641 014, Tamil Nadu, India

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Clinica Chimica Acta
Verified
Journal Article
Closed access
SMSunil Sankunny Menon
Sunil Sankunny Menon
CGChandrasekharan Guruvayoorappan
Chandrasekharan Guruvayoorappan
KSKunnathur Murugesan Sakthivel
Kunnathur Murugesan Sakthivel
RRRajan Radha Rasmi
Rajan Radha Rasmi

1 October 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
RRRajan Radha Rasmi
Rajan Radha Rasmi
KSKunnathur Murugesan Sakthivel
Kunnathur Murugesan Sakthivel
CGChandrasekaran Guruvayoorappan
Chandrasekaran Guruvayoorappan
Intracellular signalling pathways have provided excellent resource for drug development particularly in the development of cancer therapeutics. A wide variety of malignancies common in human exhibit aberrant NF-κB constitutive expression which results in tumorigenic processes and cancer survival in a variety of solid tumour, including pancreatic cancer, lung, cervical, prostate, breast and gastric carcinoma. Numerous evidences indicate that NF-κB signalling mechanism is mainly involved in the progression of several cancers which may intensify an enhanced knowledge on its role in disease particularly lung tumorigenesis. This has led to tremendous research in designing a variety of NF-κB antagonists with enhanced clinical applications through different approaches the most common being suppression of IκB kinase (IKK) beta activity. Many NF-κB inhibitors for lung cancer are now under clinical trials. Preliminary results of clinical trials for several of these agents include small-molecule inhibitors and monoclonal antibodies. A few combinatorial treatment therapies are currently under investigation in the clinics and have shown promise, particularly NF-κB inhibition associated with lung cancer.

25 March 2022 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
RRRavichandran Rakesh
Ravichandran Rakesh
LPLoganathan Chandramani PriyaDharshini
Loganathan Chandramani PriyaDharshini
KSKunnathur Murugesan Sakthivel
Kunnathur Murugesan Sakthivel
RRRajan Radha Rasmi
Rajan Radha Rasmi

1 August 2020 in Cellular Signalling
Verified
Journal Article
Closed access
LDLoganathan Chandramani Priya Dharshini
Loganathan Chandramani Priya Dharshini
SVSelvaraj Vishnupriya
Selvaraj Vishnupriya
KSKunnathur Murugesan Sakthivel
Kunnathur Murugesan Sakthivel
RRRajan Radha Rasmi
Rajan Radha Rasmi

1 November 2020 in Life Sciences
Verified
Journal Article
Closed access
SVSelvaraj Vishnupriya
Selvaraj Vishnupriya
LDLoganathan Chandramani Priya Dharshini
Loganathan Chandramani Priya Dharshini
KSKunnathur Murugesan Sakthivel
Kunnathur Murugesan Sakthivel
RRRajan Radha Rasmi
Rajan Radha Rasmi

13 April 2021 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
KSKunnathur Murugesan Sakthivel
Kunnathur Murugesan Sakthivel
SVSelvaraj Vishnupriya
Selvaraj Vishnupriya
LDLoganathan Chandramani Priya Dharshini
Loganathan Chandramani Priya Dharshini
RRRajan Radha Rasmi
Rajan Radha Rasmi
RBRamesh Balasubramanian
Ramesh Balasubramanian
Objectives: Scopoletin (6-methoxy-7-hydroxycoumarin) is a naturally occurring coumarin belonging to the category of secondary metabolites. Coumarins are commonly found in several herbs and play a prominent role in the defense mechanism of plants. Beneficial effects of scopoletin including antioxidant, anti-diabetic, hepatoprotective, neuroprotective and anti-microbial activity induced via numerous intracellular signalling mechanisms have been widely studied. However, anti-inflammation and anti-tumorigenesis properties of scopoletin are not well documented in the literature. Therefore, the primary focus of the present review was to highlight the plethora of research pertaining to the signalling mechanisms associated with the prevention of the progression of disease condition by scopoletin. Key findings: Multiple signalling pathways like nuclear erythroid factor-2 (NEF2)-related factor-2 (NRF-2), apoptosis/p53 signalling, nuclear factor-κB (NF-κB) signalling, autophagy signalling, hypoxia signalling, signal transducer and activator of transcription-3 (STAT3) signalling, Wnt-β signalling, Notch signalling are coupled with the anti-inflammation and anti-tumorigenesis potential of scopoletin. Summary: Understanding crucial targets in these molecular signalling pathways may support the role of scopoletin as a promising naturally derived bioactive compound for the treatment of several diseases.